Skip to main content

Table 4 Secondary outcome measures

From: The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis

Outcome No. of trials No. of events/total patients in cohort Effect estimate (95% CI) I 2
Omega-3 PUFA Control
Myocardial Infarction (Leng 1998 [34], Ishikawa 2010 [38]) 2 6/156 8/132 Peto OR, 0.64 (0.22, 1.88) 0%
Cardiovascular Death (Leng 1998 [34], Ishikawa 2010 [38]) 2 5/156 7/132 Peto OR, 0.60 (0.19, 1.90) 0%
Stroke (Leng 1998 [34]) 1 3/60 1/60 Peto OR, 2.79 (0.38, 20.31) NE
Angina (Ishikawa 2010 [38]) 1 5/117 8/106 RR, 0.57 (0.19, 1.68) NE
Adverse Effects      
 All Adverse Events (Gans 1990 [37], Leng 1998 [34]) 2 17/76 21/76 RR 0.81 (0.48, 1.38) NE
 Gastrointestinal Upset (Leng 1998 [34]) 1 30/60 19/60 RR 1.58 (1.01, 2.48) NE
Revascularization Surgery (Leng 1998 [34], Ishikawa 2010 [38]) 2 9/156 13/132 RR, 0.81 (0.13, 4.91) 59%
Amputation (Leng 1998 [34]) 1 0/60 1/60 Peto OR, 0.14 (0.00, 6.82) NE
Pain-Free Walking Distance (Gans 1990 [37], Leng 1998 [34], Carrero 2005 [35], Carrero 2006 [36]) 4 95 88 MD, 115.40 (-42.24, 273.05) 89%
Maximum Walking Distance (Gans 1990 [37]) 1 16 16 MD, -26.00 (-71.92, 19.92) NE
  1. Walking distances (mean differences) are expressed in metres.
  2. CI: confidence interval; MD: mean difference; NE: not estimable; OR: odds ratio; RR: risk ratio; I 2: I-squared.